Domperidon-Stoma (domperidone) tablets 0.01g. №30


Manufacturer: Ukraine

To relieve symptoms of nausea and vomiting lasting less than 48 hours.



Domperidon-Stoma Storage
active substance: domperidone;

1 tablet contains domperidone 10 mg;

Domperidon-Stoma Excipients: lactose monohydrate, potato starch, povidone, magnesium stearate.

Domperidon-Stoma Dosage form

Main physical and chemical properties: white tablets with a biconvex surface.

Pharmacotherapeutic group
Remedies used in case of functional gastrointestinal disorders. Stimulators of peristalsis. ATX code A03F A03.

Pharmacological properties


Domperidone is a dopamine antagonist with antiemetic properties. Domperidone crosses the blood-brain barrier to a small extent. Domperidone is very rarely accompanied by extrapyramidal side effects, especially in adults, but domperidone stimulates the secretion of prolactin from the pituitary gland. Its antidote action is due to a combination of peripheral (gastrokinetic) action and antagonism to dopamine receptors in the trigger zone of chemoreceptors, which is outside the blood-brain barrier in the posterior region (area postrema). Animal studies, as well as low concentrations in the brain, indicate a predominantly peripheral effect of domperidone on dopamine receptors.

Studies in humans have shown that domperidone, when administered orally, increases the pressure in the lower esophagus, improves antroduodenal motility and accelerates gastric emptying. Domperidone does not affect gastric secretion.

To relieve symptoms of nausea and vomiting.

DOMPERIDONE-STOMA is contraindicated:

patients with established hypersensitivity to the drug or to excipients;
patients with prolactin-secretory pituitary tumor (prolactinoma);
patients with severe or moderate hepatic and / or renal impairment (see sections “Pharmacological properties”, “Features of use”);
patients with a known prolongation of cardiac conduction intervals underlying cardiac disorders or diseases, in particular QTc, patients with significant electrolyte imbalance or with background heart disease such as congestive heart failure (see section “Special warnings and precautions for use”);
patients with hepatic insufficiency;
if stimulation of motor function of the stomach can be dangerous, for example, in gastrointestinal bleeding, mechanical obstruction or perforation;
contraindicated concomitant use of ketoconazole, erythromycin or other potent CYP3A4 inhibitors;
Contraindicated concomitant use of drugs that prolong the QT interval, such as fluconazole, erythromycin, itraconazole, oral ketoconazole, posaconazole, ritonavir, saquinavir, telaprevir, voriconazole, clarithromycin, amiodarone, especially dilutomycin. drugs and other types of interactions “).